Coverage of IDWeek 2017

HIVandHepatitis.com coverage of IDWeek 2017, held October 4-8, 2017, in San Diego.

• Long-Acting Monoclonal Antibody Effective Against Multidrug-Resistant HIV
• Single-Tablet Protease Inhibitor Regimen Maintains Viral Suppression for a Year

11/30/17

CROI 2017: New HCV Infections Among HIV+ Gay Men Drop By Half After DAA Roll-Out in Netherlands

A little more than a year after the Netherlands instituted a policy allowing unrestricted access to direct-acting antivirals (DAAs) for the hepatitis C treatment, researchers have already seen a dramatic decline in acute HCV infections among one at-risk population, HIV-positive men who have sex with men, according to findings reported at the Conference on Retroviruses and Opportunistic Infections this week in Seattle. 

Read more:

Coverage of the 16th European AIDS Conference

HIVandHepatitis.com and NAM coverage of the 16th European AIDS Conference (EACS 2017), October 25-27 2017, in Milan.

Read more:

CROI 2017: Are HIV/HCV Coinfected People Cured with DAAs at Increased Risk for Liver Cancer?

HIV/HCV coinfected people who are successfully treated for hepatitis C using interferon-free direct-acting antiviral (DAA) therapy do not appear to have an increased likelihood of developing hepatocellular carcinoma (HCC), according to a study presented at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.

Read more:

EACS 2017: Hepatitis C Halved among Spanish People with HIV Thanks to HCV Treatment

Spain is making dramatic progress towards eliminating hepatitis C among people living with HIV because of widespread use of direct-acting antivirals, Juan Berenguer of Hospital Gregorio Marañón in Madrid reported last week at the 16th European AIDS Conference (EACS 2017) in Milan.

Read more:

AASLD 2016: Sofosbuvir/ Ledipasvir Effective for HIV/HCV Coinfected People in Real-World Cohorts

The sofosbuvir/ledipasvir (Harvoni) coformulation used in real-world clinical practice produced good sustained virological response rates similar to those seen in clinical trials for HIV-positive people coinfected with hepatitis C, according to a pooled analysis presented at the 2016 AASLD Liver Meeting this month in Boston.

Read more:

IAS 2017: Glecaprevir/ Pibrentasvir Effective for People with HIV/HCV Coinfection

AbbVie's new 8-week pangenotypic regimen combining glecaprevir and pibrentasvir cured almost all HIV-positive people with hepatitis C coinfection in the EXPEDITION-2 study, according to a presentation at the 9th International AIDS Society Conference on HIV Science (IAS 2017) last month in Paris.

Read more:

AASLD 2016: HIV/HCV Coinfected People See Good Cure Rates in Real-World Practice in Madrid

More than 90% of HIV-positive people treated with direct-acting antivirals for hepatitis C -- including many with liver cirrhosis -- achieved sustained virological response and few discontinued treatment due to side effects, showing that real-world clinical practice can produce results as good as those seen in formal clinical trials, according to results from a Spanish study presented at the AASLD Liver Meeting this month in Boston.

Read more:

IAS 2017: Hepatitis C treatment is Effective and Feasible in Africa

Treatment for hepatitis C in sub-Saharan Africa can produce cure rates as high as those seen in industrialized countries, with high adherence and minimal side effects, according to a presentation this week at the 9th International AIDS Society Conference on HIV Science (IAS 2017) in Paris.

Read more:

Coverage of the 2016 AASLD Liver Meeting

HIVandHepatitis.com coverage of the 2016 American Association for the Study of Liver Diseases (AASLD) Liver Meeting in Boston, November 11-15, 2016.

Conference highlights include direct-acting antiviral therapy for difficult-to-treat people with hepatitis C, novel hepatitis B agents, complications of viral hepatitis, and NAFLD/NASH.

Full coverage listing by topic

The Liver Meeting website

11/20/16

Coverage of the 2017 Harm Reduction International Conference

HIVand Hepatitis.com coverage of the 2017 Harm Reduction International Conference, May 14-17, 2017, in Montreal.

Full coverage listing

HR17 website

5/31/17

Coverage of IDWeek 2016

HIVandHepatitis.com coverage of IDWeek 2016, held October 26-30 in New Orleans.

Conference highlights include experimental HIV therapies, PrEP and other biomedical HIV prevention, antibiotic resistance, and emerging infectious diseases such as Ebola virus and Zika virus.

Full listing of coverage by topic

IDWeek website

11/4/16

Coverage of the 2017 Conference on Retroviruses and Opportunistic Infections

HIVandHepatitis.com coverage of the 2017 Conference on Retroviruses and Opportunistic infections (CROI 2017), February 13-16, 2017, in Seattle.

Full coverage listing by topic

CROI website

4/16/17

Improved HIV Treatment Has Not Reduced End-Stage Liver Disease in HIV/HCV Coinfected People

Incidence of end-stage liver disease (ESLD) among HIV-positive people with viral hepatitis changed little between 1996 and 2010, despite major improvements in HIV treatment and care, investigators from Canada and the U.S. report in the November 1 edition of Clinical Infectious Diseases. 

Read more:

CROI 2017: Higher than Expected HCV Prevalence Among HIV- Gay Men in Amsterdam PrEP Program

An unexpectedly high number of HIV-negative gay and bisexual men taking pre-exposure prophylaxis (PrEP) in Amsterdam were found to have hepatitis C virus (HCV) infection, suggesting HCV is being transmitted sexually between men with and without HIV, according to a presentation last month at the Conference on Retroviruses and Opportunistic Infections in Seattle.

Read more:

AIDS 2016: AbbVie 3D and 2D Hepatitis C Combos Work Well for HIV/HCV Coinfected People

AbbVie's paritaprevir-based 3D regimen for hepatitis C virus (HCV) genotype 1 and 2D regimen for genotype 4 were shown to be highly effective and well-tolerated for HIV-positive people with HCV coinfection in the TURQUOISE-I trial, according to a report at the 21st International AIDS Conference last week in Durban.

Read more:

CROI 2017: DAA Therapy Cures HIV/HCV Coinfected People with Decompensated Cirrhosis or Transplants

HIV/HCV coinfected people with liver cirrhosis or liver failure, and those who received liver transplants, saw high rates of sustained virological response using interferon-free direct-acting antiviral (DAA) therapy for hepatitis C, according to 3 Spanish studies presented at the Conference on Retroviruses and Opportunistic Infections last month in Seattle.

Read more:

Coverage of 21st International AIDS Conference (AIDS 2016)

HIVandHepatitis.com coverage of the 21st International AIDS Conference (AIDS 2016), held July 18-22, in Durban, South Africa.

Conference highlights include PrEP and other biomedical HIV prevention, HIV cure research, experimental antiretroviral therapy, and access to treatment and prevention for key affected populations.

Full listing by topic

AIDS 2016 website

7/28/16

CROI 2017: Glecaprevir/ Pibrentasvir for HCV Can Be Safely Administered with Common Antiretrovirals

AbbVie's investigational glecaprevir/pibrentasvir treatment for hepatitis C is not expected to interact with or require dose adjustment when taken with commonly used antiretroviral regimens, offering a new option for HIV/HCV coinfected people, according to a study presented at the Conference on Retroviruses and Opportunistic Infections this month in Seattle.

Read more:

AIDS 2016: Sofosbuvir/ Velpatasvir Shows High Cure Rate in HIV/HCV Coinfection Study

The once-daily coformulation of sofosbuvir and velpatasvir was highly effective against all hepatitis C virus (HCV) genotypes and was safe and well tolerated by HIV/HCV coinfected patients in the ASTRAL-5 trial, according to results presented at the 21st International AIDS Conference (AIDS 2016)this week in Durban. A related analysis showed that sofosbuvir/velpatasvir can be safely combined with most widely used antiretrovirals, with the exception of efavirenz.

Read more: